Immuno-oncologyChina IND nod for Leads Biolabs’ LBL-024 in colorectal cancerNanjing Leads Biolabs Co. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for a phase Ib/II trial of its proprietary PD-L1/4-1BB bispecific antibody, opamtistomig (LBL-024), in combination regimens for metastatic colorectal cancer.